FMC stock: JP Morgan keeps Sell rating and EUR 32.30 target for Fresenius Medical Care stock

Published on 10/23/2026 at 16:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FMC results are due November 3, 2026. Fresenius Medical Care stock costs EUR 40.08 on October 23, 2026, plus 2.30 percent versus Xetra close.

Analyst target and reporting date

JP Morgan maintained a Sell rating and an EUR 32.30 target on October 20, 2026.
Adjusted operating income reached EUR 569.00 million in the second quarter of 2026, up 23.00 percent at constant currency.
Fresenius Medical Care stock costs EUR 40.08 at Lang & Schwarz on October 23, 2026 at 4:01 p.m. CEST, 2.30 percent above the Xetra close of October 22, 2026 at EUR 39.18.
Third-quarter 2026 results are scheduled for November 3, 2026.

3D-Architekturrender eines modernen Glas- und Stahlgebäudes mit begrüntem Vorplatz — Architektur-Render zeigt modernes Glasgebäude als Sinnbild für Fresenius Medical Care AG DE0005785802 mit minimalistischer Fassade, Illustration mit AI erstellt.

Fresenius Medical Care (ISIN DE0005785802) was the subject of a JP Morgan rating update on October 20, 2026, with the bank maintaining its Sell rating and an EUR 32.30 target, according to MarketScreener. The target is EUR 7.78 below the EUR 40.08 price, or 24.09 percent below it. At Lang & Schwarz, the stock was trading at EUR 40.08 on October 23, 2026 at 4:01 p.m. CEST, up 2.30 percent versus the Xetra close of October 22, 2026.

Second-quarter earnings improved

The most recent reported operating figures point to stronger profitability. In the second quarter of 2026, adjusted operating income rose 23.00 percent at constant currency to EUR 569.00 million, while revenue increased 4.00 percent at constant currency to EUR 4.86 billion, according to StockWatch. The company reaffirmed its full-year 2026 outlook in that report, with revenue expected near the prior-year level and operating income growth in the mid-single-digit range.

Stock position after the target

JP Morgan's EUR 32.30 target sits below the October 23 price, placing the analyst view below the market quotation rather than above it. The wider analyst picture is more mixed: MarketScreener lists 17 analysts with a mean consensus of Hold and an average target of EUR 41.86, according to the same company overview. That average is EUR 1.78 above the Lang & Schwarz price, while JP Morgan's target is EUR 7.78 below it.

Results date and valuation

Fresenius Medical Care's investor calendar schedules the third-quarter 2026 results for November 3, 2026, followed by the quarterly financial report on November 6, 2026, according to Fresenius Medical Care. The next report will give investors a fresh test of whether the second-quarter operating improvement is carrying into the second half. The company operates dialysis clinics and supplies products for kidney care.

Price and investor perspective

The October 23 quotation is EUR 0.90 above the October 22 Xetra close of EUR 39.18, equivalent to a 2.30 percent increase. The move places the stock above JP Morgan's target but below the broader average target of EUR 41.86, leaving the November results as the next dated operating checkpoint.

Fresenius Medical Care stock at Lang & Schwarz

Fresenius Medical Care stock was trading at EUR 40.08 at Lang & Schwarz on October 23, 2026 at 4:01 p.m. CEST, up 2.30 percent versus the Xetra close of October 22, 2026 at EUR 39.18. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.